This will require multiple biopsies of individual primary and secondary tumours; to date, there are no published data using this approach in mRCC but it is a method being utilised in the PREDICT consortium's pre-operative trials of mTOR and kinase inhibitors [155]. The gene discussed is MTOR; the disease is neoplasm.